UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $308

Benzinga Newsdesk www.benzinga.com Positive 80.6%

Neg 0% Neu 0% Pos 80.6%

UBS analyst A.J. Rice maintains Tenet Healthcare (NYSE:THC) with a Buy and raises the price target from $288 to $308.

Comments

No comments yet. Be the first!